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Sphingolipids are a fascinating class of signaling molecules derived from the membrane
lipid sphingomyelin. They show abundant expression in the brain. Complex sphingolipids
such as glycosphingolipids (gangliosides and cerebrosides) regulate vesicular transport
and lysosomal degradation and their dysregulation can lead to storage diseases with a
neurological phenotype. More recently, simple sphingolipids such ceramide, sphingosine
and sphingosine 1-phosphate (S1P) were discovered to signal in response to many
extracellular stimuli. Forming an intricate signaling network, the balance of these readily
interchangeable mediators is decisive for cell fate under stressful conditions. The
immunomodulator fingolimod is the prodrug of an S1P receptor agonist. Following
receptor activation, the drug leads to downregulation of the S1P1 receptor inducing
functional antagonism. As the first drug to modulate the sphingolipid signaling pathway,
it was marketed in 2010 for the treatment of multiple sclerosis (MS). At that time,
immunomodulation was widely accepted as the key mechanism of fingolimod’s efficacy
in MS. But given the excellent passage of this lipophilic compound into the brain and
its massive brain accumulation as well as the abundant expression of S1P receptors on
brain cells, it is conceivable that fingolimod also affects brain cells directly. Indeed, a
seminal study showed that the protective effect of fingolimod in experimental autoimmune
encephalitis (EAE), a murine MS model, is lost in mice lacking the S1P1 receptor on
astrocytes, arguing for a specific role of astrocytic S1P signaling in MS. In this review, we
discuss the role of sphingolipid mediators and their metabolizing enzymes in neurologic
diseases and putative therapeutic strategies arising thereof.
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THE SPHINGOLIPID SIGNALING PATHWAY
Sphingolipids have first been described by the German physician
Ludwig Thudichum, then living in London (Great Britain) in
the end of the 19th century in his book “A treatise on the
chemical constitution of the brain”. The more complex cere-
brosides) are required for cell functions such as cell recogni-
Abbreviations: AD, Alzheimer’s disease; BBB, blood-brain barrier; BDNF,
brain-derived neurotrophic factor; CNS, central nervous system; EAE, exper-
imental autoimmune encephalitis; ERK1/2, extracellular signal-regulated
kinase; GBM, multiform glioblastoma; Gd, gadolinium; HDAC, histone
deacetylase; HIF, hypoxia-inducible factor; HP, hypoxic preconditioning;
HRE, hypoxia-responsive element; IFNγ, interferon γ; IL-1β, Interleukin-1β;
LPP3, lysophospholipid phosphatase 3; LPS, lipopolysaccharide; LTP, long-
term potentiation; MRI, magnetic resonance imaging; MS, multiple sclero-
sis; PKB/Akt, protein kinase B/Akt kinase; RRMS, relapsing-remitting MS;
NMDA, N-methyl-D-aspartate; S1P, sphingosine 1-phosphate; S1P1−5, S1P
receptor types 1 to 5; S1PL, sphingosine 1-phosphate lyase; SphK1, sphin-
gosine kinase 1; SphK2, sphingosine kinase 2; SPP, sphingosine 1-phosphate
phosphatase; TNFα, tumor necrosis factor α; t-PA, tissue-type plasminogen
activator; TrkB, tropomyosin receptor kinase B; VEGFα, vascular endothelial
growth factor α.
tion, vesicular transport and lysosomal degradation and their
dysregulation can lead to storage diseases with a neurological
phenotype (Sandhoff and Christomanou, 1979), for example
Tay-Sachs disease, Sandhoff disease or Niemann-Pick disease. The
physiological relevance of sphingomyelin and its derivatives as
signaling molecules gradually came into focus during the last
decades, spurred by the discovery of sphingosine as an inhibitor
of protein kinase C (Hannun et al., 1986; Wilson et al., 1986,
reviewed by Kolesnick, 1991). Numerous reviews focus on the
intricate regulation of the sphingolipid pathway (Huwiler et al.,
2000; Hannun and Obeid, 2008; Huwiler and Pfeilschifter, 2008)
with ceramides and sphingosine 1-phosphate (S1P) functioning
as key signaling molecules (Figure 1). The pathway forms a
rheostat and the substrates are readily interconvertible. Ceramide,
which is derived either from the membrane lipid sphingomyelin
by sphingomyelinases or synthesized de novo can be induced
by many cell stressors. It acts on defined intracellular targets
(reviewed by Huwiler et al., 2000; Ruvolo, 2003) and in general
has proinflammatory and proapototic effects. It is degraded to
sphingosine, which can be phosphorylated to S1P by sphingosine
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FIGURE 1 | The sphingolipid signaling pathway. Sphingolipid signaling molecules are derived from the membrane lipid sphingomyelin and intricately
regulated forming a “rheostat” that can be imbalanced in disease states.
kinase (SphK), an enzyme that exists in two isoforms with
different subcellular distribution, SphK1 and SphK2. S1P is
an antiinflammtory, proproliferative and antiapoptotic signaling
molecule. It was first assumed to act as an intracellular second
messenger, because its cellular levels increased upon growth
factor stimulation of SphK. However, it took years to identify
the first intracellular targets of S1P, whereas it was soon dis-
covered that S1P can signal from the extracellular side through
a family of G protein-coupled receptors (GPCRs), formerly
known as Endothelial Differentiation Genes (EDG; Kluk and
Hla, 2002). Previously, they had been orphan receptors without
known ligands. In 2002, they were renamed by the IUPHAR into
S1P1−5 (Chun et al., 2002). Kawahara et al. (2009) identified
Spinster 2 (Spns2) as a specific outward transporter for S1P
(Figure 2).
Mouse models with genetic deletions of S1P receptors and the
use of pharmacological tools have been helpful to shed light on the
role of S1P in lymphocyte homeostasis, in the development of the
cardiovascular and the central nervous system (CNS), and main-
tenance of endothelial barriers (reviewed by Brinkmann, 2007).
S1P1−3 show a practically ubiquitous expression, whereas S1P4
expression is mainly detectable on leukocytes but not relevantly in
the brain, and S1P5 shows a high expression in oligodendrocytes,
the main myelinating cells of the brain. The receptors couple to
different G proteins (Gαi, Gαq, Gα12/13). From the point-of-
view of drug development, the differential receptor expression
patterns in different organs, a modulation of receptor expression
in disease states, as well as the differential coupling to G proteins,
may afford a sufficient degree of specificity to make S1P receptors
drugable targets (Figure 2).
Currently, many of the pathophysiologically relevant processes
seem to be regulated by the S1P1 receptor. Studies of S1P receptor
knockout mice showed embryonic lethality for S1P1-deficient
mice with defects in vasculogenesis and neural tube formation,
supporting the important role of this receptor in developmen-
tal processes, but not for mice deficient for one of the other
four S1P receptors. The S1P1 receptor has also been shown to
be the relevant receptor to mediate the decisive effect of the
vascular S1P gradient on the number of circulating immune
cells. S1P concentrations are close to the micromolar range
in the bloodstream and concentrations in interstitial fluids are
around three orders of magnitude lower. Most prominent are the
effects on T lymphocytes: antigen-induced activation of T cells
leads to an up-regulation of S1P1 and therefore increases the
responsiveness to S1P. S1P1 regulates T cell trafficking at multiple
stages of T cell development as well as their responses, e.g.,
thymocyte egress into the periphery, egress of mature T cells
out of lymph nodes during systemic trafficking and retention
of T cells in non-lymphoid tissues. B cells do not require S1P1
to leave the bone marrow but, like T cells, they need the
receptor to exit secondary lymphoid organs (Matloubian et al.,
2004; Ledgerwood et al., 2008; Skon et al., 2013). The egress
of other immune cells such as eosinophils (Sugita et al., 2010)
and natural killer cells (Walzer et al., 2007) also depends on
S1P receptors. In dendritic cells, the functional S1P antagonist
fingolimod increased the production of the anti-inflammatory
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FIGURE 2 | Biological functions of S1P receptor signaling. S1P signals via
five G protein-coupled receptors, termed S1P1−5. Each of the receptors
couples to several G proteins eliciting different downstream events. FTY720
phosphate activates all S1P receptors except S1P2. S1P and FTY720
phosphate are generated by intracellular phosphorylation of sphingosine and
FTY270, respectively and transported outwards to elicit signaling via S1P
receptors. Characteristically, FTY720 phosphate leads to agonist-induced
receptor internalization of the S1P1 receptor.
cytokine IL-10 and reduced IL-12 secretion (Durafourt et al.,
2011).
The vascular S1P gradient also seems to serve as a “tonic”
regulator of endothelial barrier integrity. The intricate regulation
of barrier function via cytoskeletal rearrangement with opposing
functions of the S1P receptors S1P1, S1P2 and S1P3 signaling via
small GTPases of the Rho family and the functional consequences
in several disease models have been reviewed by Xiong and Hla
(2014; Figure 2).
Besides the S1P receptors, also the SphKs catalyzing S1P
formation, SphK1 with cytoplasmic localization and SphK2, the
predominant SphK isoform in the brain, with primarily nuclear
localization (Igarashi et al., 2003) as well as the S1P degrading
enzymes S1P lyase (S1PL; Le Stunff et al., 2002), S1P phosphatases
(SPP1 and SPP2), and the lysophospholipid phosphatase 3 (LPP3;
Brindley and Pilquil, 2009) have been found to be altered in
several neurological diseases and also represent putative targets
for drug development (Figure 1).
DISCOVERY AND DEVELOPMENT OF FINGOLIMOD/FTY720
The substance fingolimod (also known as FTY720) has made
a very long and interesting journey from traditional asian
medicine to a drug tested in large scale international multicenter
randomized-controlled placebo-or standard of care-controlled
trials proving its efficacy in the treatment of multiple sclerosis
(MS) (reviewed by Im, 2003). It evolved from derivatization of
ISP-1 that has been isolated from the fungus Isaria sinclairii.
This fungus contributes to the fascinating phenomenon of “veg-
etable wasps and plant worms”, also termed “vegetative wesps”
or “winter-insect and summer-plant” according to its Chinese
characters, caused by the fungus infecting the living insect host,
feeding on it during winter time and growing out of the host
insect’s cadaver in summer (Fujita et al., 1994). ISP-1 showed 10-
100fold greater immunosuppressant activity than ciclosporin A in
experimental models (Fujita et al., 1994) and was modified for less
gastric toxicity to fingolimod (Kiuchi et al., 2000). In contrast to
all known immunosuppressants known at that time, fingolimod
acts via a sequestration of circulating mature lymphocytes to the
lymph nodes (Chiba et al., 1998) without major alterations of
their immune functions such as cytokine secretion (Yanagawa
et al., 1998), and thus seemed to promise the prevention of
allograft rejection without a severe general immunosuppression
(reviewed by Brinkmann et al., 2000). Inspired by the structural
similarity of FTY720 to sphingosine (Figure 3) and the fact that
S1P receptors had been identified on lymphocytes, Brinkmann
et al. (2002) discovered that fingolimod was phosphorylated by
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FIGURE 3 | Phosphorylation of fingolimod generates a structural analog
to S1P. Fingolimod shows high analogy to sphingosine and is
phosphorylated by spingosine kinases, mainly SphK2, which is the
predominant SphK isoform in the brain. Fingolimod is a prodrug of fingolimod
phosphate that can signal via S1P receptors and activate intracellular targets
of S1P.
SphKs to fingolimod phosphate and targeted S1P receptors and
thereby could prevent experimental autoimmune encephalitis
(EAE), the rodent disease model for MS, in rats. Mandala et al.
(2002) provided evidence for lymphocyte sequestration in the
lymph nodes secondary to S1P receptor activation. Matloubian
et al. (2004) established the S1P1 receptor to be essential for
sensing of the S1P gradient by lymphocytes leading to recircu-
lation and regulation of lymphocyte egress from both thymus
and peripheral lymphoid organs. The inhibition of lymphocyte
recirculation by fingolimod argues for a functional antagonism
of fingolimod phosphate at the S1P1 receptor. Indeed, Gräler and
Goetzl (2004) described a downregulation of S1P receptors upon
treatment with fingolimod and Pham et al. (2008) showed in
vivo that treatment with fingolimod reduced membrane expres-
sion of S1P1 on lymphocytes. This proposed functional antag-
onism of fingolimod at S1P1 is in line with the observation
that mutant mice that express an internalization-defective S1P1
have delayed lymphopenia kinetics in response to fingolimod
(Thangada et al., 2010) and that a lymphocytic knock-down
of S1P1 also inhibits their egress from thymus (Allende et al.,
2004).
Fingolimod was advanced into large scale randomized con-
trolled trials to prevent allograft rejection in patients with
renal transplantations but finally its further development was
abandoned because high doses (2.5 mg/d and 5 mg/d) did not
provide sufficient immunosuppression to allow reduction of co-
immunosuppressants and was not superior to standard care.
There was an increased incidence of macular edema and transient
decreases in heart rate (reviewed by Mansoor and Melendez,
2008). Since 10–100–fold lower doses than those required in
animal models of organ graft survival had been highly efficient
in EAE (Brinkmann et al., 2010), the focus of clinical develop-
ment shifted from transplant medicine to MS as an autoimmune
disease.
Fingolimod might also have receptor-independent effects on
inflammation, especially by binding to intracellular targets of S1P
(Hait et al., 2014) or interacting with metabolism and signaling
of other lipids. Fingolimod can inhibit both S1P generating as
well as degrading enzymes such as SphK1 (Lim et al., 2011), S1PL
(Bandhuvula et al., 2005), the ceramide synthases (Lahiri et al.,
2009) and the acid sphingomyelinase (ASM; Dawson and Qin,
2011; Figure 4).
Ceramides could also play a role in MS pathophysiology
(Qin et al., 2010; Schiffmann et al., 2012) and evidence for
an interaction of fingolimod with ceramides has been shown
(van Doorn et al., 2012). Fingolimod also appears to inhibit the
cannabinoid receptor CB1 (Paugh et al., 2006), which has been
shown to have some proinflammatory properties in EAE (Zhang
et al., 2009). Additionally, fingolimod can inhibit phospholipase
A2 (PLA2) activity in mast cells and therefore prostaglandin and
thromboxane secretion (Payne et al., 2007). This could contribute
to the therapeutic effect of fingolimod in MS, as PLA2 has been
shown to be highly expressed in EAE plaques (Kalyvas and David,
2004) and arachidonic acid is increased in cerebrospinal fluid of
MS patients (Dore-Duffy et al., 1991).
CLINICAL EFFICACY OF FINGOLIMOD IN
RELAPSING-REMITTING MULTIPLE SCLEROSIS
MS is an autoimmune disease of the CNS. The primary mech-
anism is the aberrant formation of autoreactive immune cells
directed against CNS antigens. Upon passing the blood-brain
barrier (BBB), they meet their antigen and incite inflammatory
demyelination leading to subacute neurological symptoms that
can remit and, given the chronicity of the disease, relapse. In
the early inflammatory phase of the disease, immunomodulation
with beta-interferons or glatiramer acetate have been shown to
slow disease progression. In later stages of the disease, neurode-
generative processes also play a role.
Fingolimod was approved by the regulatory authorities world-
wide as the first oral agent to treat relapsing-remitting multiple
sclerosis (RRMS) after the successful completion of two phase III
studies in 2010 showed its efficacy. FREEDOMS (Kappos et al.,
2010) was a placebo controlled trial and TRANSFORMS (Cohen
et al., 2010) even showed the superiority of fingolimod over
treatment with intramuscular interferon beta-1a, the standard of
care for RRMS. FREEDOMS showed a relative reduction of the
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FIGURE 4 | Fingolimod interacts with sphingolipid metabolizing enzymes. Inhibitory effects on SphK1 (Lim et al., 2011), S1PL (Bandhuvula et al., 2005),
ceramide synthases (Lahiri et al., 2009) and the acid sphingomyelinase (ASM; Dawson and Qin, 2011) have been shown. NSM—neutral sphingomyelinases.
relapse rate by 54–60% and a corresponding effect on disability
progression (Kappos et al., 2006). TRANSFORMS showed similar
relapse rates, although no significant effect on disability. FREE-
DOMS II, another Phase III placebo controlled trial (Calabresi
et al., 2014) initiated by Novartis recently, could reproduce the
positive effect of fingolimod on relapse rate. In clinical practice,
due to its presumed superiority over interferon beta, fingolimod
is one of the first line therapeutic choices for highly active
RRMS.
Besides the positive effect on clinical outcome, previous clin-
ical trials (Kappos et al., 2006; Comi et al., 2010) as well as
the following phase III studies FREEDOMS, TRANSFORMS and
FREEDOMS II have shown effects of fingolimod on magnetic
resonance imaging (MRI) outcomes: Gadolinium (Gd) enhanced
lesions, the morphological correlates of clinical as well as sub-
clinical relapses, were reduced in the fingolimod treatment group
compared to the patients receiving interferon beta-1a or placebo.
Gd enhancement indicates BBB leakage, which is one of the
initial steps in the pathophysiological cascade resulting in a MS
plaque. Furthermore, BBB failure is a hallmark of almost every
inflammatory reaction in the CNS. Another secondary endpoint
of some of the studies cited above was brain atrophy—which
was also reduced in fingolimod treated patients. The reduction
of Gd-positive lesions demonstrates a direct or indirect anti-
neuroinflammatory effect of fingolimod in patients, whereas the
relatively crude parameter brain atrophy might be attributable to
a direct neuroprotective mechanism or secondary to a reduced
accumulation of MS plaques and secondary neurodegeneration.
As expected from the preceding animal studies, peripheral
lymphocyte counts of fingolimod-treated patients are signifi-
cantly reduced as compared to patients receiving placebo and
interferon beta-1a (Cohen et al., 2010; Kappos et al., 2010). In
contrast to other cytotoxic immunosuppressive drugs resulting
in lymphopenia, the effect of fingolimod on the peripheral cir-
culation of subsets of lymphocytes is reversible (Boulton et al.,
2012). In line with the available experimental data, other studies
showed that fingolimod selectively inhibits the egress of CCR7-
positive naive and central memory T lymphocytes from the lymph
node of treated patients (Pham et al., 2008). Effector memory cells
represent the largest T cell population in the blood of patients
receiving fingolimod and are important to maintain immune
competence (Masopust et al., 2001). Furthermore, these cells did
not lose the capacity to produce interferon-γ (IFNγ; Mehling
et al., 2008). On the other hand, the CD4+TH17 subset of lym-
phocytes, which are trapped by fingolimod is believed to have a
more pro-inflammatory role in the pathophysiology of MS (Lock
et al., 2002; Tzartos et al., 2008). TH17 cells produce proinflam-
matory IL-17 and IL-22, transmigrate efficiently across the BBB,
disrupt tight junctions, highly express neurotoxic substances, and
promote CNS inflammation through additional CD4+ T cell and
neutrophil recruitment (Kebir et al., 2007). In fingolimod-treated
patients, the remaining CD8+ T cells are less responsive to the
chemokine CCL2 (Johnson et al., 2010) and, therefore, probably
less likely recruited to sites of antigen-induced inflammation
(Carr et al., 1994). Fingolimod also strongly reduces certain sets
of B cell counts in the blood of MS patients (Kowarik et al., 2011).
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The remaining lymphocyte populations appear to be sufficient
to protect patients against most infections (Francis et al., 2014).
However, there is some evidence for more viral infections, e.g.,
severe herpes/varizella virus reactivation (Cohen et al., 2010),
pointing towards a compromised T cell function. The broad range
of immune regulatory functions of fingolimod seen in patient
blood samples and those of experimental animals goes far beyond
lymphocyte trafficking and has recently been reviewed by Garris
et al. (2014).
In summary, the clinical data on the efficacy of fingolimod
in RRMS is robust and has been shown in several independent
phase III trials. Additional drugs that modulate S1P signaling are
in the pipeline, some of them in advanced clinical trials (reviewed
by Bigaud et al., 2014). The dose of 0.5 mg/d approved for MS
treatment, which is decisively lower than doses used in animal
models to treat EAE, also leads to peripheral lymphopenia and
other immune cell mediated effects in patients. But the MRI find-
ings that fingolimod has unequivocal effects on BBB disruption
and brain atrophy suggests additional direct effects of fingolimod
in brain cells.
FINGOLIMOD IN EXPERIMENTAL MODELS OF MULTIPLE
SCLEROSIS
Fingolimod was first shown to be effective in EAE in the rat by
Brinkmann et al. (2002) at a dose of 0.3 mg/kg/d. Later studies
confirmed these results in different models of MS and different
species (Webb et al., 2004; Kataoka et al., 2005). The suppression
of EAE in mice and rats by fingolimod correlated with reduced
numbers of lymphocytes in the blood and the CNS (Brinkmann
et al., 2002; Kataoka et al., 2005).
Besides a prophylactic effect, which is comparable to relapse
prevention in patients, a therapeutic effect could also be shown
(Kataoka et al., 2005). Even a very late-initiated treatment is
able to reverse paralysis (Balatoni et al., 2007), downregu-
lates inflammatory genes such as matrix metalloproteinases and
reduces BBB leakiness (Foster et al., 2009). This effect is only
one of the mechanisms which appears to be independent of
the “classical” role of fingolimod in lymphocyte trafficking. In
EAE several additional effects on the immune system have been
shown: Fingolimod changes CD8+ effector T cell function and
inhibits their cytotoxic function by inhibition of cytosolic PLA2
and the reduction of IFNγ and Granzyme B expression. Inter-
estingly, this effect appears to be independent of S1P recep-
tor modulation as fingolimod phosphate did not elicit these
effects (Ntranos et al., 2014). In some EAE-studies, the effect
of fingolimod on CNS physiology was analyzed. The observed
clinical benefit was accompanied by improvement of electro-
physiological abnormalities (Balatoni et al., 2007), demyelination
(Papadopoulos et al., 2010) and synaptic dysfunction (Rossi et al.,
2012).
At least some of these outcome parameters might be due to
an additional effect of fingolimod directly within the CNS. Fin-
golimod readily penetrates into the CNS and accumulates in the
brain and in the spinal cord (Foster et al., 2007). S1P receptors are
expressed in cells of the CNS. Interstingly, short-term fingolimod
administration can fail to suppress EAE, albeit producing a rapid
and substantial reduction of lymphocyte counts (Foster et al.,
2007). Moreover, neurological deficits reappear before lympho-
cyte numbers normalize if treatment with fingolimod is stopped
(Webb et al., 2004). CYM-5442, an S1P1-selective fingolimod
analog that leads to significant levels of the drug in CNS but not
in plasma, also improves the disease course in EAE. There was
no persisting lymphopenia in these mice but a cyclical recovery
from lymphopenia. Nevertheless, S1P1 expression on neurons and
astrocytes was reduced, and levels of cytokines in the CNS were
suppressed (Gonzalez-Cabrera et al., 2012).
Furthermore, in alternative MS models, which are based on
lymphocyte-independent demyelination, an effect of fingolimod
could be observed: Fingolimod enhances remyelination following
demyelination of organotypic cerebellar slices (Miron et al., 2010)
and in the cuprizone model (Kim et al., 2011), although there
is some controversy about the latter model (Hu et al., 2011).
Another animal model for MS is the delayed-type hypersensitivity
model (DTH) in Lewis rats. Again, an effect of fingolimod could
be shown independently of lymphocyte infiltration and BBB
leakage (Anthony et al., 2014).
So what could be the cellular target of fingolimod within
the CNS? There is accumulating evidence for a specific role of
astrocytes, a cell type which is supposed to play an important
role in MS pathophysiology (Brosnan and Raine, 2013). Strong
evidence points to an anti-inflammatory effect of fingolimod on
astrocytes in vitro (Wu et al., 2013). A particularly illuminating
study of Choi et al. (2010) made use of a conditional, cell-
specific knock down of the S1P1 receptor on all cells of the
CNS (nestin-cre), neurons (synapsin-cre) and astrocytes (GFAP-
cre). They found that S1P1-deficiency on astrocytes led to an
attenuation of EAE and that the protective effect of fingolimod
in EAE was lost in mice with astrocytic but not with neuronal
S1P1 deletion (Choi et al., 2010). Finally, therapeutic adminis-
tration of fingolimod to EAE mice has specific effects on astro-
cyte activation and nitric oxide production (Colombo et al.,
2014).
Oligodendrocytes also express S1P receptors, especially the
S1P5 receptor, which shows a relatively restricted expression pat-
tern. Interestingly, genetically modified mice with S1P5 deficiency
do not show defects in myelination (Brinkmann, 2007). At least in
vitro and in slice cultures direct effects of fingolimod on myelina-
tion could be shown (Miron et al., 2008, 2010). A possible role for
microglia in the therapeutic effect of fingolimod can be derived
from studies of so called microvesicles. They were shown to be
significantly reduced in EAE mice treated with fingolimod and are
increased in cerebrospinal fluid of MS patients (Verderio et al.,
2012). Furthermore, fingolimod treatment leads to a reduced
microglial production of pro-inflammatory cytokines such as
tumor necrosis factor α (TNFα), interleukin 1β (IL-1β), and
interleukin 6 (IL-6; Noda et al., 2013).
An analysis of fingolimod’s effects in EAE clearly points
towards several contributing mechanisms. Beyond the effect on
lymphocyte trafficking, a direct immunmodulatory effect as well
as direct effects of fingolimod in the CNS seem to be involved.
As new, more receptor-specific agents will enter the scene in the
future, it is possible that we will realize that fingolimod as a rather
“dirty” drug acting on multiple targets may even prove to be
superior to receptor-specific agents.
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STROKE
Stroke is an acute brain attack caused by the sudden thromboem-
bolic occlusion of a brain vessel with the consequence of cerebral
ischemia, the more frequent cause of stroke, or by a rupture of
a brain artery causing a hemorrhage into the brain parenchyma.
These different stroke entities show the same clinical presentation
consisting of a focal neurological deficit such as hemiparesis or
aphasia of sudden onset.
CEREBRAL ISCHEMIA
The embolic blockade of a brain vessel leads to hypoperfusion
of the dependent vascular territory in the brain with an almost
immediate loss of brain function. However, we know from exper-
imental studies (Astrup et al., 1981) and clinical imaging (Thijs
et al., 2002) that the affected brain tissue remains viable for a few
hours with the infarct gradually expanding from the core to the
periphery of the hypoperfused territory. This is the pathophysio-
logic correlate of a therapeutic time window for vessel recanaliza-
tion with thrombolytics or catheter-based interventions. The only
approved stroke therapy to date is thrombolysis with recombinant
human tissue-type plasminogen activator (t-PA), which is safe
and effective within 4.5 h after symptom onset (Lees et al., 2010).
The pathophysiological cascades taking place in the ischemic
brain are well characterized and can be roughly summarized by
the three interleaving phenomena of excitotoxicity, inflammation
and apoptosis (Dirnagl et al., 1999).
In recent years, experimental stroke research has produced
strong evidence that cellular immunity and especially T cells
play a decisive role in the fate of brain tissue following cerebral
ischemia. Different experimental strategies aiming at a reduction
of lymphocyte counts such as the use of genetic models (Hurn
et al., 2007; Kleinschnitz et al., 2010); splenectomy prior to
stroke (Ajmo et al., 2009), immunosuppressive drugs (Sharkey
et al., 1996) or the induction of lymphocytic tolerance (Becker
et al., 1997) have shown therapeutic efficacy in experimental
stroke models. Therefore, to test the potent immunomodulator
fingolimod with its specific lymphocyte-directed immunomod-
ulation in experimental stroke models was a straightforward
approach.
Meanwhile, over 10 experimental studies have shown thera-
peutic efficacy of fingolimod in stroke models in mice and rats
(Czech et al., 2009; Shichita et al., 2009; Hasegawa et al., 2010;
Pfeilschifter et al., 2011a,b; Wei et al., 2011; Kraft et al., 2013)
with doses from 0.25 to 1 mg/kg applied systemically, leading to
a robust lymphocytopenia in rodents (Czech et al., 2009). Repro-
ducible therapeutic effects on lesion size and functional outcome
were accompanied by a reduction in pro-apoptotic processes in
the infarcted brain areas such as reduced nuclear translocation of
apoptosis inducing factor (AIF; Czech et al., 2009), less caspase-
3 cleavage and TUNEL positive neurons (Hasegawa et al., 2010),
and an activation of pro-survival pathways such as extracellular
signal-regulated kinase (ERK1/2), protein kinase B/Akt kinase
(PKB/Akt) and Bcl-2 upregulation (Hasegawa et al., 2010; Wei
et al., 2011). Cell culture experiments did not show relevant
neuroprotection by fingolimod in neuronal cells subjected to
“ischemia in the dish” stimuli such as glutamate, H2O2 or hypoxia
(Wei et al., 2011; Kraft et al., 2013) but a reduced inflammatory
activation of microvascular brain endothelial cells (Wei et al.,
2011). Most topical, Kraft et al. (2013) found a reduction of
microvascular thromboses in the periinfarct area after fingolimod
treatment, a phenomenon that has been observed also previ-
ously by the group secondary to several T cell-directed therapies
(Kleinschnitz et al., 2013). Since these findings argue for a role of
lymphocytes to boost microvascular thrombus formation in cere-
bral ischemia, they coined the term thromboinflammation. Of
note, there was also one study that reported no therapeutic effect
on lesion size and outcome in two different stroke models despite
efficient systemic lymphocyte depletion, and decreased cerebral
lymphocyte infiltration (Liesz et al., 2011). Similar findings were
reported in a recent study on traumatic brain injury (TBI) by
Mencl et al. (2014), who assessed the effect of FTY720 in two
different experimental models of TBI mimicking focal and diffuse
brain injury. FTY720 applied directly prior to the induction of
the brain lesion did not reduce lesion size or improve functional
neurological outcome neither early or 1 week after the induction
of the brain lesion, even though it led to a reduced infiltration
of neutrophils and macrophages and/or a reduced microglial
activation. TBI, however, is a clearly different entity of brain
injury than ischemic stroke. The role of circulating immune cells
in lesion development after TBI is less unequivocal and there is
most probably not as much microvascular endothelial activation
as in ischemic stroke.
Concerning the signaling pathway mediating the protective
effect of fingolimod, Hasegawa et al. (2010) demonstrated that
this therapeutic effect could also be elicited by the S1P1-selective
agonist SEW2871 and abrogated by the S1P1/S1P3-selective com-
petitive antagonist VPC23019, argueing for an S1P1-mediated
effect. This assumption was supported by findings of Pfeilschifter
et al. (2011b) showing that the neuroprotective effect of fin-
golimod is lost in SphK2 deficient mice, which cannot efficiently
phosphorylate and thus activate fingolimod, arguing against a
direct effect of non-phosphorylated fingolimod. Hasegawa et al.
(2013) examined the expression of the SphK and the S1P1 recep-
tor in the ischemic area with a focus on neurons 6 h and 24 h
after stroke by immunohistochemistry, and found a significantly
decreased expression of S1P1, SphK1, and SphK2 starting at 6 h
and significant at 24 h after MCAO. Labeling of S1P1 and both
SphKs was reduced in the infarct cortex but remained present in
the periinfarct cortex, allowing fingolimod to be phosphorylated
and act via inside-out signaling on the S1P1 receptor.
In analogy to the findings of Choi et al. (2010) in the EAE
model, it could be possible that the protective effect of fingolimod
only partially depends on the peripheral immunomodulation and
also relies on direct effects in the CNS. To weigh the effect of
lymphocyte depletion against other putative mechanisms, Kraft
et al. (2013) applied fingolimod to recombination activating gene-
1 (Rag1)-deficient mice that are devoid of T and B lymphocytes.
While these mice per se developed smaller infarcts than wild type
mice, they were not further protected by fingolimod, showing
that the neuroprotective effects of fingolimod largely depends on
immunomodulation.
Stroke-associated infections, especially pneumonia, are the
most important factor of mortality in the acute phase.
They are promoted by a stroke-associated immunodepression
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 283 | 7
Brunkhorst et al. Fingolimod in neurological diseases
(Meisel et al., 2005) and will have to be considered prior to
any clinical application of fingolimod in the context of stroke.
In an experimental stroke model, Pfeilschifter et al. (2011b)
did not find an increase of bacterial colonalization in the
lungs of fingolimod-treated animals in comparison to con-
trol animals 24 h after stroke. Beyond the acute phase, the
fate of stroke survivors is mainly determined by the suc-
cess of rehabilitative stroke care aiming at functional recov-
ery. Brunkhorst et al. (2013) showed that fingolimod applied
from day 3 to day 7 (1 mg/kg b.i.d.) after a photothrombotic
lesion directed to the motor cortex of mice relevantly ame-
liorated functional impairment over an observation period of
31 days, reduced astroglial scarring and increased the size of
post-synaptic densities. In this model, fingolimod increased the
expression of the trophic factor vascular endothelial growth
factor α (VEGFα) but not of brain-derived neurotrophic fac-
tor (BDNF), which has been shown to increase secondary to
fingolimod treatment in other models of neurodegenerative
diseases.
Another event of importance in the context of stroke, but
also intensive care medicine and transplant surgery, which has
been shown to be regulated by S1P and fingolimod is precon-
ditioning. Following the principle of “what does not kill you
makes you stronger”, preconditioning is a process that uses a sub-
lethal noxious stimulus to induce or increase tolerance towards
a second noxious stimulus. In stroke research, well established
preconditioning stimuli include hypoxic preconditioning (HP),
transient ischemia, inhalational anesthetics such as isoflurane or
inflammatory agents such as bacterial lipopolysaccharide (LPS).
HP is based on a hypoxia-induced stabilization of hypoxia-
inducible factor (HIF) that is continuously degraded by an
oxygen-sensing degradative pathway under normoxic conditions.
Stabilized by hypoxia, HIF, which exists in three isoforms, binds to
hypoxia-responsive elements (HRE) of hypoxia-regulated genes
to promote their transcription. Besides hypoxia and ischemia,
also non-hypoxic stimuli such as isoflurane (Sun et al., 2013) or
LPS (He et al., 2014) can stabilize HIF. SphK2, but not SphK1
has been shown to be upregulated by HP and isoflurane in the
brain (Wacker et al., 2009; Yung et al., 2012) in a HIF-dependent
manner (Wacker et al., 2012) and pharmacological inhibition
(Wacker et al., 2009) and genetic deletion of SphK2 (Wacker
et al., 2012; Yung et al., 2012) were shown to abrogate the pro-
tective effects of preconditioning in experimental stroke. There
are conflicting findings whether genetic deletion of SphK2, the
predominant SphK isoform in the brain (Blondeau et al., 2007)
per se exacerbates ischemic damage in stroke or not (Pfeilschifter
et al., 2011b; Yung et al., 2012). In other cell systems, HIF-
mediated upregulation has also been shown for SphK1 (Ader
et al., 2008; Schwalm et al., 2008) and both isoforms contain
HREs in their respective promotor regions. Wacker et al. (2009,
2012) showed that fingolimod given 48 h prior to stroke also
reduced lesion size and had a strong synergistic effect in con-
juction with HP. Therefore, they concluded that fingolimod is a
preconditioning agent. While the protective effect after a remote
pretreatment 48 h prior to the insult could be explained by the
long-lasting lymphocyte depletion after a single dose of FTY720
(Chiba et al., 1998) and the accumulation of fingolimod in the
brain (Foster et al., 2007), the finding that coadministration of
R59949, which inhibits HIF accumulation was able to abolish
the protective effect of remote fingolimod pretreatment (Wacker
et al., 2012) clearly suggests that HIF-mediated gene regulation
is downstream of fingolimod. The finding of Yung et al. (2012)
that HIF-1α stabilization following isoflurane preconditioning is
lost in SphK2-deficient mice also supports a regulation of HIF-
mediated signaling by S1P. In synthesis, these findings suggest
that in the context of preconditioning and stroke, the signaling
between SphK2 and its products fingolimod phosphate or S1P
is bidirectional with an induction of SphK2 following precon-
ditioning stimuli and a lost efficacy of HIF-stabilizing factors in
SphK2-deficient mice on the one hand and a HIF-dependency of
the preconditioning effect of fingolimod on the other hand. The
preconditioning effect of HP, the HIF stabilizer cobalt chloride,
and of fingolimod was abolished by pretreatment with the S1P1-
specific antagonist W146, supporting an auto- and paracrine
propagation of preconditioning by the S1P1 receptor. Function-
ally, SphK2 deficiency not only abrogates the neuroprotection by
HP but also BBB preserving effects of HP by an alteration in the
expression of adhesion molecules in homogenated cortical brain
tissue from SphK2-deficient mice analyzed 48 h after the hypoxic
stimulus in comparison to WT mice (Wacker et al., 2012).
THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR (t-PA)
The vascular S1P gradient with high concentrations in the blood-
stream and low concentrations in the interstitial fluids is generally
viewed as a tonic barrier preserving mechanism for endothelial
barriers (reviewed by Xiong and Hla, 2014). Several reports of the
efficacy of S1P or fingolimod in experimental states of vascular
leakage such as acute lung injury (Peng et al., 2004) or anaphylaxis
(Camerer et al., 2009) have sparked interest on a putative thera-
peutic effect of fingolimod on BBB disruption after stroke that
contributes to potentially fatal brain edema. So far, the data from
experimental stroke models on this question are not unequivocal.
Cerebral ischemia induces BBB disruption and the thrombolytic
t-PA has been shown to aggravate this process (Latour et al., 2004)
which accelerates with time from symptom onset, representing
the underlying cause of an increased bleeding risk associated with
late t-PA treatment, the main obstacle to a more widespread use of
this stroke therapy. In a model of moderate size thromboembolic
stroke, a faithful model for recanalization by t-PA treatment,
fingolimod reduced infarct growth and BBB disruption secondary
to late application of t-PA (Campos et al., 2013). By contrast,
in a model of large hemispheric strokes and t-PA treatment,
fingolimod did not show a beneficial effect (Cai et al., 2013).
These contradictory findings can in part be reconciled by the
possibility that this massive infarction might have led to an overly
rapid loss of SphK and S1P receptors in the infarct and periinfarct
region explaining a non-response to fingolimod treatment. Con-
cerning possible future clinical trials of fingolimod in stroke, this
would argue against the inclusion of patients with severe stroke
symptoms and massive infarctions on brain imaging.
INTRACEREBRAL HEMORRHAGE
Intracerebral hemorrhage (ICH) is often denoted as “the most
untreatable cause of stroke” because there is no causal treatment
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and it is charged with a high mortality. Noteworthy, Asian
populations display higher rates of ICH, with ICH representing
over 30% of all first ever strokes in China in a meta-analysis
of population-based studies (Tsai et al., 2013). Fingolimod has
shown therapeutic efficacy in experimental models of ICH
(Rolland et al., 2011, 2013; Lu et al., 2014) with a reduced infil-
tration of CD3+ lymphocytes and reduced endothelial ICAM-1
expression. Rolland et al. (2013) conducted a 10 week follow-
up of their experimental animals after ICH induction and a
single injection or a 3-day course of 1 mg/kg FTY720 and
auspiciously found an improved outcome in neurocognitive
scores and brain atrophy with a stronger effect in the animals
treated for 3 days. These findings support the observations of
a proregenerative effect of FTY720 by Brunkhorst et al. (2013).
Lu et al. (2014) described a reduction of apoptotic cell death
both in the center and at the edge of the hematoma but no
alteration of in the numbers of CD68+ monocytes/macrophages
and resident microglia and also reported positive long-term
results concerning neurological function and brain atrophy after
2 weeks.
Recently, a first clinical trial was conducted in China, which
recruited 23 patients with deep primary ICH. They were ran-
domized to a treatment with placebo or 0.5 mg/d FTY720
(Gilenya®) orally for 3 consecutive days (Fu et al., 2014). This
very small clinical trial did not detect differences in adverse
events such as increased susceptibility to infections. The group
reported an improvement of magnetic resonance imaging-based
measurements of perihematomal edema volume, but the patient
number seems too small to draw valid conclusions about efficacy
yet.
NEURODEGENERATIVE DISEASES
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is the most common age-related neu-
rodegenerative disorder and shows a rising prevalence along
with global trends towards increasing life spans. AD leads to a
cognitive decline that is attributable to neuronal loss predom-
inantly affecting higher cortical functions (visuospatial orienta-
tion, memory, planning and execution of activities, language and
arithmetics) whereas cognitive working tempo and drive seem
unaltered. Patients are often able to maintain an unremarkable
“façade” even in later stages of the disease when brain atro-
phy, predominantly of the hippocampus and the temporal lobe
can be seen in clinical brain imaging. Currently, there is no
causal treatment of this devastating disease. While the disease-
triggering mechanisms are yet unknown, the neuropathologi-
cal hallmarks of AD consist of the deposition of amyloid-β
(Aβ) plaques and the formation of neurofibrillary tangles con-
sisting of hyperphosphorylated tau protein (Braak and Braak,
1991, 1995). Following an ascending course from the entorhinal
region to the neocortex, these changes are accompanied by a
loss of cortical synapses, which correlates with cognitive decline
(DeKosky and Scheff, 1990). Inflammatory processes such as
activation of microglia and astrocytes as well as production
of inflammatory cytokines occur within and around amyloid
plaques (Lukiw and Bazan, 2006). Recently, autopsy studies on
brains of AD patients but also data from experimental dis-
ease models of AD have provided evidence that alterations of
the sphingolipid linked to the pathological mechanisms of AD
and that S1P receptor modulation by fingolimod represents a
promising therapeutic approach reducing both the production
(Takasugi et al., 2013) and the neurotoxicity (Asle-Rousta et al.,
2013; Doi et al., 2013; Hemmati et al., 2013; Fukumoto et al.,
2014) of Aβ peptide. Aβ is produced from Aβ precursor pro-
tein (APP) in the amyloidogenic pathway through sequential
cleavage by two aspartate proteases, β- and γ-secretases (Zheng
and Koo, 2011). Several studies have implicated cholesterol and
sphingolipid-rich membrane microdomains, termed lipid rafts,
in the amyloidogenic processing of APP, and the activities of the
secretases are influenced by the composition of these lipid rafts
(Kalvodova et al., 2005; Osenkowski et al., 2008; Holmes et al.,
2012).
There is ample evidence that the sphingolipid metabolism is
altered in AD brains, leading to an accumulation of proapoptotic
and proinflammatory ceramides (Han et al., 2001). The expres-
sion of the ceramide-generating acid and neutral sphingomyeli-
nases (NSM) has been shown to be upregulated in brains of
patients suffering from AD (Filippov et al., 2012) and elevated
ceramide levels are linked to an inhibition of glycolysis (Arboleda
et al., 2007) and the induction of nitric oxide synthase and
oxidative stress (Cutler et al., 2004). Cutler et al. showed elevations
of cholesterol levels and ceramide species (especially C18 and
C24) that gradually increased in correlation to disease severity
in brain samples from AD patients and over time in a murine
model of AD. The accumulation of ceramide species or cholesterol
in cultured hippocampal neurons could be reversed by anti-
oxidative treatment with α-tocopherol. Mechanistically, this may
be attributed to an activation of the neutral sphingomyelinase
by Aβ, as Jana and Pahan (2010) had shown previously that
Aβ induces neutral sphingomyelinase in an NADPH-dependent
pathway leading to ceramide accumulation that has a propapo-
totic effect on cultured neurons. Elevated ceramide levels stabilize
the Aβ-cleaving enzyme BACE-1 (Puglielli et al., 2003) whereas
a reduction of ceramide levels in turn leads to a reduced secre-
tion of APP and Aβ in human neuroblastoma cells (Tamboli
et al., 2005), indicating a vicious cycle involving Aβ production,
cellular stress and ceramide accumulation. The clinical signif-
icance of increased ceramide levels in the pathophysiology of
AD is supported by studies on patient serum and CSF samples
that indentified ceramide species as potential biomarkers of AD
(Mielke et al., 2014) and HIV-associated dementia (Bandaru et al.,
2007).
Less is known about the role of S1P, the functional opponent of
ceramide, in the development of AD. An analysis of post-mortem
brain tissues of 9 individuals with a clinical and histopatholog-
ical diagnosis of AD and 6 age-matched control individuals by
He et al. (2010) revealed a pattern of elevated ASM and acid
ceramidase (AC) expression in AD, along with a reduction in
sphingomyelin and elevation of ceramide. Sphingosine levels were
higher in the AD brains, but levels of the downstream lipid medi-
ator S1P were reduced. This finding was corroborated by a very
recent study of Couttas et al. (2014) reporting on sphingosine/S1P
levels and SphK activity in post-mortem brain samples from 34
individuals. Not all of the patients had received a clinical diagnosis
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of AD and the cohort was composed of carriers of the protective
apolipoprotein (APO) ε2 genotype as well as the risk-bearing
APO ε4 genotype. In this cohort, the S1P to sphingosine ratio was
higher in hippocampal regions of Apo ε2 carriers and S1P levels
declined in a regiospecific manner most strongly in brain regions
with the most advanced histopathological changes. The activity
of SphK1 and SphK2, which generate S1P from sphingosine, also
decreased with higher histopathological disease scores. Besides a
loss of SphK activity, lower S1P levels in AD patients could also
be explained by increased activities of the S1P degrading enzymes
S1PL and S1PP. Indeed, S1PP1 has been shown to be markedly
up-regulated in AD brains using microarray technology (Katsel
et al., 2007).
Seemingly in contrast to these findings, Takasugi et al. (2011)
described that the activity of β-site APP cleaving enzyme-1
(BACE1), the major β secretase and rate-limiting enzyme for
amyloid-β peptide (Aβ) production, is positively modulated by
S1P in mouse neurons. They found that β-cleavage of APP was
inhibited by genetic knockdown of the S1P-generating SphKs
in cultured neuronal cells, an effect that was more pronounced
when SphK2 was targeted, or by pharmacological inhibition with
the SphK-selective inhibitor SKII. Congruently, increasing S1P
levels via inhibition of S1PL or the S1PP1 enhanced Aβ secretion.
Modifications of extracellular levels of the poorly permeating lipid
mediator S1P failed to modulate BACE1 activity and BACE1 was
specifically pulled down to matrices carrying S1P. Therefore Taka-
sugi et al. (2011) concluded that the S1P-BACE1 interaction was
of a direct intracellular nature and not mediated via membrane-
bound S1P receptors. Translating these findings into a mouse
model of AD, they found a protective effect of the SphK inhibitor
SKII against Aβ secretion. Since SphK2 is the predominant iso-
form of the two S1P synthesizing enzymes in the brain (Blondeau
et al., 2007) they analyzed SphK2 expression levels and activity
in brain specimens from AD patients in comparison to non-
demented individuals. While the overall SphK2 protein levels were
decreased in the brains of individuals suffering from dementia,
which was explained by progressive neuronal loss and the pre-
dominantly neuronal expression of SphK2 in the brain (Blondeau
et al., 2007) the relative in vitro activitiy of SphK2 normalized
to SphK2 protein levels was significantly increased in AD brains
(Takasugi et al., 2011). Due to the normalization of total SphK2
protein levels, these findings do not necessarily stand in contrast
to the above-mentioned observations of Couttas et al. (2014)
who found a decreased SphK activity of both isoenzymes in post-
mortem brain specimens from individuals with histopathological
features of AD.
A very recent report from Karaca et al. (2014) on the influence
of S1P levels in models of S1PL deficiency on APP metabolism
sustained detrimental effects of elevated intracellular S1P levels
concerning Aβ accumulation. This group found that inhibi-
tion of SphK2 reduced the accumulation of amyloidogenic C-
terminal fragments of APP whereas genetic deletion of S1PL or
downregulation by siRNA, which both were effective in raising
intracellular S1P levels, increased their accumulation. This effect
could be mimicked by extracellular addition of the easily cell-
permeating sphingosine but not by extracellular addition of the
polar mediator S1P. Karaca et al. found that the processing of
APP C-terminal fragments to Aβ1-40 and Aβ1-42 was reduced
due to an impaired γ-secretase activity in S1PL-deficient cells and
APP C-terminal fragments accumulated in the lysosomal com-
partments, along with a deregulated expression of other lysosomal
proteins and an impairment of the final stage of autophagy. Inter-
estingly, these pathophysiological processes could be alleviated
by a mobilization of intracellular calcium from the endoplasmic
reticulum, a process that has been shown to be impaired in a
model for the lysosomal storage disease Nieman Pick type C
(Lloyd-Evans et al., 2008).
Concerning a putative therapeutic effect of fingolimod on AD
progression in experimental models of established disease, there
are several reports presenting promising evidence. In a model of
intrahippocampal injection of Aβ1-42 in rats, a 2 week course
of fingolimod treatment (1 mg/kg daily i.p.) ameliorated spatial
learning and memory in the Morris water maze test at the end
of the 2 week course and reduced neuronal damage and caspase-
3 activation in the hippocampus (Asle-Rousta et al., 2013). Of
note, fingolimod did not enhance learning and memory in control
animals who received saline injections into the hippocampus.
Fingolimod showed equal efficacy as the NMDA receptor antag-
onist memantine, an approved drug to treat AD symptoms in
the same disease model (Hemmati et al., 2013) and both were
able to partly reverse changes of the gene expression pattern
induced by Aβ injection. So far, the mechanism underlying these
therapeutic effects is not yet clear. It is possible that the systemic
immunomodulation dampens the inflammatory reaction to Aβ
deposition. Specifically, fingolimod may interfere with the migra-
tion of phagocytes in the brain since it has been shown to reduce
Aβ-triggered whole blood cell migration along an Aβ gradient in
a Boyden chamber assay in a dose-dependent manner (Kaneider
et al., 2004).
Takasugi et al. (2013) analyzed the effects of fingolimod and
the S1P1-specific receptor agonist KRP203 on Aβ production
in cultured neuronal cells and brain Aβ levels in a murine AD
model (Takasugi et al., 2013). In cell culture, they found a dose-
dependent reduction of Aβ production by both compounds.
Contrary to S1P, fingolimod and KRP203 affected the activity
of γ- but not β-secretases. Phosphorylation of both compounds
by SphK2 was a prerequisite for their activity as demonstrated
by pharmacological inhibition and genetic knockdown of this
enzyme. The effects of fingolimod and KRP203 seem to be
receptor-independent since Aβ production was not affected by
the S1P1 agonist SEW2871 or the S1P1 antagonist W123, and
neither W123 nor the Gαi protein inhibitor suramin altered
the inhibition of Aβ production by fingolimod. These findings
point towards intracellular effects of fingolimod requiring prior
phosphorylation by SphK2, and this hypothesis was further cor-
roborated by the finding that extracellular addition of the polar
fingolimod phosphate, which poorly permeates cell membranes,
also did not effect Aβ production. Takasugi et al. translated these
findings into an animal model of transgenic mice overexpressing
human APP and could show opposite effects of a short-course
treatment with fingolimod (0.5 mg/kg for 6 days) on the produc-
tion of Aβ1-40 (decreased) and Aβ1-42 (increased), thus showing
that fingolimod affects Aβ levels also in vivo (Takasugi et al.,
2013).
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Furthermore, direct effects of fingolimod on brain cells have
been shown, such as a dose-dependent induction of BDNF pro-
duction in cultured neurons on mRNA and protein levels that
inhibited Aβ-induced neurotoxicity in a dose-dependent fashion
(Doi et al., 2013). The trophic effects of BDNF were shown to be
mediated via the tropomyosin receptor kinase B (TrkB) involving
the main downstream pathway ERK1/2 phosphorylation. BDNF
was also induced by fingolimod in a murine AD as shown by a
BDNF ELISA from mouse brain homogenates (Fukumoto et al.,
2014). The translational relevance of these findings is further
sustained by the fact that BDNF expression levels are lower in
patients with AD.
ANIMAL MODELS OF LEARNING AND MEMORY
There is increasing evidence that S1P signaling also plays a
physiological role in learning processes. S1P has been shown to
increase glutamate release from presynaptic terminals in the CA3
pyramidal neurons of the hippocampus in an S1P3 receptor-
dependent manner (Kanno et al., 2010). S1P induced the translo-
cation of S1P3 receptors to presynaptic mossy fiber terminals in
the CA3 region and long term potentiation depending on the
mossy fiber—CA3 pyramidal neuron interaction was inhibited by
a SphK inhibitor, an effect that could be reversed by addition of
S1P. Again, the positive effect of S1P on long-term potentiation
(LTP) could be inhibited by S1P3 receptor antagonism. SphK1
is highly expressed in mossy fibers of the hippocampus and LTP
was significantly impaired in SphK1 knockout mice, showing that
SphK1 is required for hippocampal S1P generation. Congruently,
mice with genetic deletion of SphK1 showed an impairment
of spatial learning and memomory in the Morris water maze.
Interestingly, somewhat opposing findings have recently been
described by Hait et al. (2014), see below.
Topical work of the last few years has established a role for
coagulation factors such as thrombin, plasmin and activated
protein C (aPC) and protease-activated receptors (PAR) in hip-
pocampal learning processes (Maggio et al., 2008; Mannaioni
et al., 2008; Yuan et al., 2009). Interestingly, Maggio et al. (2014)
characterized aPC as a metaplastic molecule that enhances LTP
upon delivery of a subthreshold stimulation. They propose a
model in which upon binding to the endothelial protein C recep-
tor, which is also expressed on astrocytes, aPC activates PAR1,
which triggers the SphK-dependent production of S1P. In turn,
S1P binds to the S1P1 receptor and stimulates intracellular Ca2+
stores, ultimately leading to enhanced LTP.
Very recently, Hait et al. (2014) showed that fingolimod affects
learning and memory function by epigenetic regulation of gene
expression. After SphK2 dependent phosphorylation, fingolimod
phosphate binds to class 1 histone deacetylases (HDAC), some
of the few defined targets of intracellular S1P signaling (Hait
et al., 2009). Primary hippocampal neurons as well as a neu-
roblastoma cell line showed a robust, predominantly nuclear
expression and activity of SphK2, showing abundant fingolimod
phosphorylation within hours of fingolimod treatment. Most of
the fingolimod phosphate remained intracellularly, and interfer-
ing with SphK2 expression crucially regulated fingolimod phos-
phate levels. Interestingly, treatment with fingolimod reduced
nuclear S1P levels, probably by competition for phosphorylation
by SphK2. As shown for S1P in non-neuronal systems (Hait
et al., 2009), fingolimod treatment led to histone acetylation,
and the negative modulation of this effect by SphK down-
regulation in a cell membrane-free system of highly purified
nuclei as well as the inefficacy of extracellularly-added S1P or
fingolimod phosphate showed that this is a purely intracellu-
lar inhibitory effect of phosphorylated fingolimod on HDAC
activity while the activity of histone acetyltransferases, which
have opposing effects, is not influenced by S1P or fingolimod
phosphate.
To test the physiological relevance of these observations and
following reports on the role of epigenetic regulation, especially
histone acetylation in memory and learning processes (Fischer
et al., 2010), Hait et al. (2014) chose an experimental model
of contextual fear extinction to evaluate the effects of FTY720
on learning and memory in vivo. To exclude well-established
complex effects of the immune system on cognitive functions
(Kipnis et al., 2004; Brynskikh et al., 2008), T and B cell deficient
severe combined immunodeficiency (SCID) mice were used. The
contextual fear extinction test evaluates freezing as an expression
of acquired fear secondary to an adversive stimulus, and fear
extinction upon re-exposure to the same environment without
this stimulus and hence is a model for how the individual
reduces fear-related reactions to a no longer dangerous stimu-
lus, a mechanism that is impaired in anxiety disorders. Here,
fingolimod, which accumulated in the hippocampus, did not
change fear acquisition and fear extinction, but alleviated delayed
extinction deficits in comparison to saline-treated SCID mice.
By contrast, performance in paradigms of tone-dependent fear
conditioning that is acquired independently of the hippocam-
pus, exploratory behavior, basal anxiety-like behavior and spatial
learning were not influenced by fingolimod treatment in SCID
mice. The amelioration of contextual fear extinction in the foot-
shock model was accompanied by increased histone acetylation
in the hippocampus and alterations in gene expression of genes
linked to synaptic plasticity and learning. In electrophysiological
recordings from hippocampal slices, Hait et al. (2014) could show
that like other HDAC inhibitors, fingolimod increased LTP as a
marker of synaptic plasticity. To confirm the role of SphK2 in
hippocampal learning processes and especially SphK2 dependent
phosphorylation of fingolimod, they used SphK2 deficient mice,
which spontaneously showed impaired visuospatial memory in
the Morris water maze and decreased contextual fear extinction.
Consistent with the hypothesis that nuclear phosphorylation of
fingolimod by SphK2 is a prerequisite of HDAC inhibition, fin-
golimod failed to rescue fear extinction in this model.
HUNTINGTON DISEASE
Huntington disease (HD) is an inherited neurodegenerative brain
disease with autosomal-dominant inheritance. It is characterized
by mutations of the huntingtin gene with extended CAG trin-
ucleotide repeats encoding a dysfunctional mutant huntingtin
protein (mHtt). mHtt forms aggregates that are cytotoxic and
interfere with many physiological cell functions, such as the
expression of neurotrophins, e.g., BDNF (Zuccato et al., 2001).
mHtt accumulation has also been shown to influence lipid
metabolism (Maglione et al., 2010) and intraventricular infusion
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of ganglioside GM1 induced phosphorylation and detoxification
of mutant huntingtin (Di Pardo et al., 2012). Clinically, this
disease which predominantly affects the striatum and the cortex
manifests as a hyperkinetic movement disorder with unvoluntary
dance-like movements accompanied by a cognitive and psycho-
social decline. Symptoms usually begin around the age of 40
and characteristically show an “anticipation” (earlier onset and
heavier symptoms from generation to generation) that is linked to
an increasing extension of the CAG repeats. Di Pardo et al. (2014)
assessed a potential therapeutic effect of fingolimod in transgenic
mice expressing exon 1 of the human HD gene carrying a CAG
repeat (line R6/2). These mice develop a progressive neurological
phenotype with motor symptoms resembling those seen in HD
(Carter et al., 1999). Daily fingolimod injections over several
weeks, starting in the subtle phase of HD symptoms, significantly
ameliorated motor signs of HD and prevented weight loss usually
associated with this disease but had no effect on motor tests in
WT mice. This was accompanied by activation of the prosurvival
pathways of PKB/Akt and ERK1/2 in the striatum. Fingolimod-
treated R6/2 mice showed a reduction of brain atrophy and a dra-
matic reduction of mHtt aggregates in comparison to untreated
mice. Fingolimod was able to partially prevent the reduction in
corpus callosum thickness that is observed in R6/2 mice compared
to WT mice, a hint towards brain-specific and disease-modifying
properties of this drug, which were also supported by increases
in DARPP-32, a specific marker of medium spiny neurons and
myelin-associated glycoprotein (MAG), a marker of myelin and
white matter integrity in R6/2 mice after fingolimod treatment.
DiPardo et al. also found a significant increase of cortical BDNF
mRNA levels both in R6/2 and WT mice treated with FTY720 and
the treatment improved cortical neuronal activity. Interestingly,
FTY720-treated mice showed a less pronounced loss of GM1 gan-
gliosides in the striatum, so one putative protective mechanism of
FTY720 is preventing the disturbance of the lipid balance.
RETT DISEASE
Rett disease is a rare congenital neurodegenerative disease with
postnatal onset, usually at the age of 6–18 months, linked to
a mutation in the MeCP2 gene located on the x chromosome.
Typical for this disease is a relatively normal appearance of
infants at birth followed by a developmental regression with
severe motor and cognitive deficits. So far, there is no causal
treatment. Experiments with MeCP2 -deficient mice have shown
an improvement of symptoms by the administration of a small
molecule agonist to the neurotrophin receptor TrkB that is acti-
vated by BDNF (Schmid et al., 2012). The fact that BDNF levels
in MeCP2 mice did not increase in the first weeks after birth as
in WT mice (Kolbeck et al., 1999; Chang et al., 2006) as well
as a more severe phenotype of MeCP2 null mice crossed with
BDNF-deficient mice or an ameliorated phenotype if MeCP2
null mice were crossed with mice overexpressing BDNF (Chang
et al., 2006) pointed towards an influence of BDNF on the
course of Rett disease. Furthermore, mice lacking MeCP2 and
BDNF in neurons show behavioral similarities (Rauskolb et al.,
2010). This makes MeCP2-deficient mice a useful tool to study
functional consequences of therapies that raise BDNF levels in
the brain. Due to its excellent brain permeability, its confirmed
neuroprotective properties in models of cerebral ischemia and the
fact that it activates ERK1/2 in neurons–a pathway that is activated
by BDNF via the TrkB receptor–prompted Deogracias et al. (2012)
to investigate the effects of fingolimod on BDNF levels and disease
severity in MeCP2 knockout mice. They found that fingolimod
phosphate increased BDNF mRNA and protein in a time- and
dose-dependent manner in cultured neuronal cells that were
shown to express the S1P receptors S1P1−3. The phosphorylation
of ERK1/2 and PKB/Akt that occurred in parallel could be shown
to be S1P1 dependent by use of specific agonists and antagonists
whereas it was not further clarified whether BDNF induction
was an S1P receptor-mediated or direct intracellular effect. In
organotypic cortical cultures, Deogracias et al. (2012) showed
that addition of fingolimod phosphate increases network activity
and by addition of a monoclonal BDNF-blocking antibody could
prove that BDNF is in part responsible for this increased activity.
This neutralizing BDNF antibody also reversed the antiapoptotic
effect of fingolimod phosphate protecting neurons from NMDA-
induced death. In vivo, treatment of healthy animals with fin-
golimod led to increased ERK1/2 phosphorylation and BDNF
levels in cortical neurons. In the Rett disease model of MeCP2-
deficient mice, a 4 week course of fingolimod treatment at a
rather low dose (0.5 mg/kg every 4d) lead to increased levels of
BDNF in affected brain structures and even to an amelioration
of motor impairment and survival. This was the first description
of a fingolimod-elicited production of the neurotrophin BDNF
which could be attributed primarily to neurons by immuno-
histochemistry and cell culture experiments while a relevant
contribution of astrocytes could be excluded (Deogracias et al.,
2012).
EPILEPSY
Epilepsy is a chronic neurological disorder characterized by repet-
itive seizures, either of genetic (caused by mutations of genes
encoding for excitatory or inhibitory signal tranducers in neurons
or glial cells) or structural (caused by a brain lesion such as
cerebral infarcts or brain tumors) origin. While epilepsies are
well controllable by anticonvulsant medication in the majority
of cases, series of recurrent seizures or non-terminating status
epilepticus represent a serious threat for patients with epilepsy.
The processes happening in the propagation from single seizures
to prolonged epileptic activity have been characterized in exper-
imental models and emcompass cell death, axonal and dendritic
plasticity, neurogenesis and neuroinflammation (Lukasiuk et al.,
2006). Especially neuroinflammatory processes such as glial cell
activation and increases in inflammatory cytokines such as IL-
1β and TNFα have recently gained interest (Ravizza et al., 2011;
Vezzani and Friedman, 2011) and the blockade of IL-1β (Maroso
et al., 2011) or TNFα (Rao et al., 2008) were shown to effectively
decrease seizure activity. Gao et al. (2012) reported a significant
decrease in the incidence and duration of spontaneous recurrent
seizures by fingolimod treatment in rats that were subjected
to an experimental model of lithium/pilocarpine-induced status
epilepticus. Rats were treated with fingolimod 1 mg/kg daily
starting 24 h after the induced status epilepticus and showed a
reduced activation of microglia and astrocytes in the hippocam-
pus in comparison to vehicle-treated mice as well as reduced
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hippocampal expression of the proinflammatory cytokines IL-1β
and TNFα. Concerning a putative effect on neurons, there was
abundant staining for the neuronal marker NeuN in immunohis-
tochemical stainings of the hippocampus of healthy rats that was
lost to a great degree 4 days after status epilepticus and partially
rescued by FTY720 treatment. The loss of NeuN-positive Neurons
in the hippocampus was accompanied by mossy fiber sprouting
which was also reduced by treatment with FTY720.
Concerning putative non-immunomodulatory effects of
FTY720 in epilepsy, it should be noted that mice with a genetic
deletion of the S1P2 receptor develop spontaneous, sporadic,
and occasionally lethal seizures between 3 and 7 weeks of age
(MacLennan et al., 2001). At a cellular level, loss of the S1P2 recep-
tor leads to a large increase in the excitability of neocortical pyra-
midal neurons, demonstrating that S1P2 plays an essential and
functionally important role in the control of neuronal excitability.
BRAIN TUMORS
Primary brain tumors most commonly originate from glial cells.
Among them, high grade gliomas such as the glioblastoma mul-
tiforme (GBM) are the most malignant forms with aggressive
growth and invasion of the surrounding brain tissue. Due to their
infiltrating nature, they cannot be completely excised and the
majority will recur locally (Giese et al., 2004). Life expectancy
of patients diagnosed with GBM operated and treated with
radiotherapy ranges around 12 months and can be extended
by chemotherapy with the DNA alkylating chemotherapeutic
temozolomid (TMZ), the current standard of care (Hart et al.,
2013). There is increasing evidence that dysregulations of S1P
metabolizing enzymes with increased levels of S1P are corre-
lated with malignant properties of GBM. Van Brocklyn et al.
(2005) showed that high expression levels of the SphK isoform
SphK1 in human astrocytomas correlates with a 3fold shorter
median survival of patients whereas in glioblastoma cell lines,
RNA interference to knock down SphK2 even had a greater effect
on tumor cell proliferation than knock down of SphK1 (Van
Brocklyn et al., 2005). Exogenously added S1P has been found
to stimulate motility and invasiveness of human GBM cells (Van
Brocklyn et al., 2003). GBM cell lines express the S1P receptors
S1P1, S1P2 and S1P3. From cellular the lower affinity S1P receptor
ligands dihydro-sphingosine and sphingosylphosphorylcholine in
the high nanomolar to low micromolar range, Van Brocklyn et al.
(2002) concluded that the proproliferative effects of S1P on astro-
cytic tumor cell lines are mediated by the S1P1 receptor involving
PI3K and ERK1/2 activation rather than by intracellular effects of
S1P. This is supported by (partial) abolishments of S1P effects by
the Gi protein inhibitor pertussis toxin or the phosphatidylinosi-
tol 3-kinase (PI3K) inhibitors wortmannin and LY294002 and the
ERK1/2 kinase inhibiting MEK inhibitor U0126.
A thorough analysis of Young and Van Brocklyn (2009) on
the contribution of the single S1P receptors to glioma cell pro-
liferation, migration and invasiveness by means of differential
overexpression or RNAi knockdown of the receptors on glioma
cell lines established that S1P1, S1P2 and S1P3 all contribute posi-
tively to S1P-stimulated glioma cell proliferation, with S1P1 being
the major contributor. Stimulation of glioma cell proliferation by
these receptors correlated with activation of ERK1/2. Activation
of S1P5 inhibited glioma cell proliferation and ERK1/2 activation.
S1P1 and S1P3 enhance glioma cell migration and invasion. S1P2
inhibited migration through Rho activation, Rho kinase signaling
and stress fiber formation, but enhanced invasiveness of glioma
cells by stimulating cell adhesion. Thus, while S1P2 decreases
glioma cell motility, it may enhance tumor cell invasion (Van
Brocklyn et al., 2003; Lepley et al., 2005).
This may be in part mediated through induction of pro-
teins that modulate glioma cell interaction with the extracellular
matrix. S1P2 potently enhances expression of CCN1/Cyr61, a
matricellular protein which stimulates cellular adhesion, migra-
tion, angiogenesis and invasion. A neutralizing antibody to CCN1
blocked S1P2-stimulated glioma invasion (Van Brocklyn et al.,
2003). Expression of CCN1 has been shown to correlate with
tumor progression and poor patient prognosis in glioma patients
(Xie et al., 2004a) and to enhance tumorigenicity of glioma cells
(Xie et al., 2004b). Besides that, uPA and its receptor uPAR, have
been established as critical mediators of tumor cell invasiveness
(Andreasen et al., 1997). In a subsequent study, Young et al.
(2009) found that both CCN1 and uPA are upregulated in a
GBM cell line upon treatment with S1P (100 nM). The expres-
sion of both proteins was induced through different individual
S1P receptor subtypes that were overexpressed in a GBM cell
line that normally expresses very low levels of S1P receptors.
S1P1 and S1P2 receptors contribute to CCN1 induction while all
three receptors, with S1P1 being the most potent, contribute to
induce expression of members of the uPA system. Neutralizing
antibodies directed against uPA or CCN1 significantly decreased
both basal and S1P-stimulated GBM cell invasiveness. uPA activity
and glioma invasion were potently blocked by SphK inhibition.
Thus, the SphK/S1P/S1P receptor subtypes have a profound and
coordinated effect on expression of several genes which are known
to be involved in GBM invasiveness (Young et al., 2009).
Growth factors, including EGF, are known to stimulate SphK1
in several cell types and their overexpression in tumor cells is
often associated with worse prognosis (Salomon et al., 1995).
Especially the EGF receptor (EGFR) is often overexpressed and
mutated in gliomas (Frederick et al., 2000). Estrada-Bernal et al.
(2011) showed that treatment of glioma cell lines with EGF led to
increases in SphK1 expression and activity. Expression of the con-
stitutively active EGFRvIII mutant in glioma cells mimicked this
effect. In addition, siRNA to SphK1 partially inhibited EGFRvIII-
induced growth and survival of glioma cells as well as ERK1/2
activation. Interestingly, this effect could be overridden by treat-
ment with high concentrations (10 µM) of S1P but not by lower
concentrations. Since 10 µM S1P have been shown to activate
the intracellular S1P target TRAF2, while lower concentrations
of S1P (10 nM) are sufficient to activate the membrane-bound
receptors, this hints to receptor-independent intracellular effects
(Alvarez et al., 2010). Pharmacological blockade of the EGFR by
gefetinib had a rather modest inhibitory effect on glioma cell pro-
liferation whereas pharmacological inhibition of SphK1 strongly
blocked proliferation and induced apoptosis of a GBM-derived
neurosphere cell line (Estrada-Bernal et al., 2011). These data
showed that EGF/EGFR and EGFRvIII signaling induces SphK1
in glioblastoma cells and that SphK1 is necessary to maintain
survival of glioblastoma cells.
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A putative therapeutic effect of fingolimod in the context of
glioma research was evaluated as early as 2001 (Sonoda et al.,
2001), spurred by the finding that higher concentrations of fin-
golimod in the micromolar range were shown to induce apop-
tosis in mature T lymphocytes (Enosawa et al., 1996). Sonoda
et al. found that fingolimod at rather high concentrations (ED50
between 1–10µg/ml) induced apoptosis in the human glioma cell
line T89G. FTY720 led to tyrosine dephosphorylation of the focal
adhesion kinase (FAK) and inhibited the protective FAK/PI3K
pathway leading to an activation of caspase 6. Conversely, the
inhibition of protein tyrosine phosphatases by orthovanadate
prevented FAK dephosphorylation and inhibited fingolimod-
induced cell death. An antitumor effect of fingolimod has been
described in many tumor cell types (reviewed by Pitman et al.,
2012; Zhang et al., 2013). In most cases, these antitumor effects
are caused by unphosphorylated fingolimod, not fingolimod
phosphate in cell culture systems and seem to involve direct
intracellular effects of fingolimod such as an activation of phos-
phatase 2A (PP2A), the tumor suppressor PTEN, an inhibition of
the PI3K/AKT/mTOR pathway or even an inhibition of SphKs.
Estrada-Bernal et al. (2012) reproduced the propapoptotic effect
of fingolimod on glioma cells in the pathophysiologically more
relevant model of brain tumor stem cells (BTSCs) derived from
human GBM tissue. These cells develop neurosphere-like aggre-
gates in cell culture and develop into faithful histological models
of human gliomas when injected into the brains of mice. Four dif-
ferent BTSC lines underwent apoptosis at FTY720 concentrations
of 1µg/ml and higher whereas toxicity to non-malignant primary
astrocytes began at 10µg/ml and was thus one order of magnitude
higher. Fingolimod led to a rapid dephosphorylation of ERK1/2,
upregulation of the BH3-only protein Bim, and cleavage of cas-
pases 9 and 7 or caspase 3. Fingolimod also reduced BTSC inva-
siveness and, most importantly, had a synergistic effect in addition
to TMZ, the current standard chemotherapeutic agent to treat
malignant gliomas, allowing a reduction of the fingolimod dose
required for BTSC toxicity. By contrast, fingolimod phosphate
was much less effective at inducing apoptosis of BTSC. Generally,
in animal models of many cancers, exceedingly high FTY720
doses of 5–10 mg/kg are required for satisfying effectiveness, as
compared to 0.5–1 mg/kg that were found to be effective in
models of cerebral ischemia (Czech et al., 2009; Hasegawa et al.,
2010; Wei et al., 2011; Kraft et al., 2013) or neurodegeneration
(Deogracias et al., 2012; Takasugi et al., 2013) and even lower
doses required in EAE (Brinkmann et al., 2002). This was also
described in the experimental glioma model of Estrada-Bernal
et al. (2012), who injected glioma BTSCs into nude mice that
were treated with either fingolimod (10 mg/kg), TMZ (5 mg/kg)
or a combination of both drugs. This experiment confirmed the
efficacy of fingolimod as an experimental glioma therapy that
significantly prolonged survival and reduced tumor growth even
though it was somewhat less effective than TMZ. The combi-
nation of both drugs showed the greatest efficacy. Even if due
to yet undefined reasons, the in vivo effect of fingolimod was
somewhat weaker than the stunning in vitro effects, fingolimod
seems to be a promising (adjuvant) drug to treat gliomas, whose
progression is yet barely controlled by the current standard ther-
apies.
SUMMARY AND FUTURE PERSPECTIVES
According to experimental data, the sphingolipid signaling path-
way seems to be of central relevance in the pathophysiology
of many diverse neurological diseases. The versatile sphingosine
analog fingolimod, prodrug of the S1P-modulating fingolimod
phosphate, provides scientifically proven reduction of relapse
rate and amelioration of disease progression in MS. But data
from experimental animal models suggest that fingolimod has
additional therapeutic applications in store. Many of the diseases
reviewed here follow a fatal course and treatment options yet are
scarce and their efficacy often short-lived. Given the growing body
of experience with fingolimod accumulated by clinical neurolo-
gists and the favorable safety profile in the indication of MS, there
is hope for a translation of some of these experimental findings
into the clinics.
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